| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense) | 3,466 | 3,817 | 2,917 | 3,573 |
| Income (loss) before income taxes | -39,625 | -23,483 | 114,157 | - |
| Provision for income taxes | -1,278 | 0 | 1,278 | - |
| Net income (loss) | -38,347 | -23,483 | 112,879 | -26,430 |
| Unrealized gain on marketable securities | 350 | 200 | 47 | 181 |
| Total other comprehensive gain | 350 | 200 | 47 | 181 |
| Comprehensive income (loss) | -37,997 | -23,283 | 112,926 | -26,249 |
| Earnings per share, basic, total | -0.65 | -0.4 | 1.95 | -0.47 |
| Earnings per share, diluted, total | -0.65 | -0.4 | 1.9 | -0.47 |
| Weighted average number of shares outstanding, basic, total | 58,611,677 | 58,353,855 | 57,862,674 | 56,341,074 |
| Weighted average number of shares outstanding, diluted, total | 58,611,677 | 58,353,855 | 59,398,600 | 56,341,074 |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)